Lonza Group AG (OTCMKTS:LZAGY – Get Free Report) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 200 shares, a drop of 98.9% from the November 15th total of 18,600 shares. Based on an average daily trading volume, of 286,800 shares, the short-interest ratio is currently 0.0 days.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently commented on LZAGY shares. The Goldman Sachs Group upgraded Lonza Group to a “strong-buy” rating in a report on Wednesday, October 9th. Redburn Atlantic raised Lonza Group to a “strong-buy” rating in a research note on Wednesday, November 27th.
Check Out Our Latest Report on LZAGY
Lonza Group Price Performance
Lonza Group Company Profile
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.
Read More
- Five stocks we like better than Lonza Group
- How to Calculate Inflation Rate
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Are Penny Stocks a Good Fit for Your Portfolio?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- 3 Consumer Discretionary Stocks Ready for a Comeback in 2025
Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.